James Morrow, MD, PhD

Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Image
Faceless Avatar - Male

James Morrow, MD, PhD

Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Instructor of Pediatrics, Harvard Medical School
Education
Graduate School
Case Western Reserve University
Cleveland
OH
Medical School
Case Western Reserve University
Cleveland
OH
Residency
Boston Combined Residency Program (BCRP)
Boston
MA
Fellowship
Dana-Farber Cancer Institute
Boston
MA
Certifications
American Board of Pediatrics (General)
Professional History

Dr. Morrow received his bachelor’s degree in biology with highest honors at Pennsylvania State University. He attended medical school at Case Western Reserve University, where he was selected as an HHMI-NIH Research Scholar. During this fellowship James worked in the pediatric oncology branch at the National Cancer Institute (NCI), studying the molecular mechanisms of solid tumor metastasis.

James went on to complete a PhD, splitting research time between Case Western and NCI. His research showed that gene enhancer dysregulation is a key driver of osteosarcoma metastasis. James completed his pediatric residency in the Boston Combined Residency Program at Boston Children’s Hospital. He then completed his Pediatric Hematology/Oncology Fellowship at Dana-Farber Cancer Institute.

James is currently an attending physician treating children and adolescents with cancer and hematologic diseases. He is also completing research in the lab of Bradley Bernstein at DFCI, studying the developmental origins and evolution of pediatric solid tumors.

Publications

Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. View Abstract
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. View Abstract
Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. View Abstract
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. View Abstract
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. View Abstract
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. View Abstract
Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. View Abstract
Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. View Abstract
mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. View Abstract
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. View Abstract
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. View Abstract
RET mutation and expression in small-cell lung cancer. View Abstract